Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?

Authors:

Published: 0000-00-00

DOI: HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27275

Keywords:

Abstract:

Source: